Intramuscular delivery of rAAV-mediated kallikrein gene reduces hypertension and prevents cardiovascular injuries in model rats

Acta Pharmacologica Sinica

Volumn 28, Issue 12, 2007, Pages 1898-1906

  Wang, Tao ^a   Hou, Ling Bo ^a   Liu, Zhen Jun ^a   Wang, Yan ^a   Chen, Chun Lian ^a   Xiao, Xiao ^a,b   Wang, Dao Wen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cardiovascular remodeling; Gene therapy; Human tissue kallikrein; Hypertension; Intramuscular administration; Recombinant adeno associated virus vector; Spontaneously hypertensive rat

Indexed keywords

PARVOVIRUS VECTOR; TISSUE KALLIKREIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC TRANSDUCTION; HEART PROTECTION; HUMAN; HUMAN CELL; HYPERTENSION; HYPERTROPHY; KIDNEY INJURY; NONHUMAN; RAT; SYSTOLIC BLOOD PRESSURE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BASE SEQUENCE; CARDIOVASCULAR DISEASES; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; GENETIC VECTORS; HYPERTENSION; KALLIKREINS; MALE; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; RECOMBINATION, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 36649013455     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2007.00677.x     Document Type: Article

References (26)

1. Kitamura NKH, Fukushima D, Takagaki Y, Miyata T, Nakaniski S. Structural organization of the human kininogen gene and a model for its evolution. J Biol Chem 1985 260:8610 7.
2. Müller-Esterl W IS, Nakaniski S. Kininogens revisited. Trends Biochem Sci 1986 11:336 9.
3. Nakaniski SSP. Precursor and kininogen: their structures, gene organizations, and regulation. Physiol Rev 1987 67:1117 42.
4. Adam AAA, Caloy G, Closset J, Damas J, Franchiment P. Human kininogens of low and high molecular mass: quantification by radioimmunoassay and determination of reference values. Clin Chem 1985 31:423 6.
5. harma JNUK, Noor AR, Rahman AR. Blood pressure regulation by the kallikrein-kinin system. Gen Pharmacol 1996 27:55 63.
6. Katori MMM. Pivotal role of renal kallikrein-kininsystem in the development of hypertension and approaches to new drugs based on this relationship. Jpn Pharmacol 1996 70:95 128.
7. Margolius HS. Kallikreins and kinins: some unanswered questions about system characteristics and roles in human disease. Hypertension 1995 26:221 9.
8. Xiong WCJ, Chao L. Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hypertension 1995 25 (4 Pt 2 715 9.
9. Murakami HYK, Chao L, Chao J. Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats. Kidney Int 1998 53:1305 13.
10. Chao JZJ, Lin KF, Chao L. Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy and renal injury in Dahl salt-sensitive rats. Hum Gene Ther 1998 9:21 31.
11. Chao JZJ, Lin KF, Chao L. Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats. Kidney Int 1998 54:1250 60.
12. Dobrzynski EYH, Chao J, Chao L. Adenovirus- mediated kal-likrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats. Immunopharma-cology 1999 44:57 65.
13. Wang TL, Zhao C, Chen C, Li J, Chao J, Chao L, et al. Recom-binant adeno-associated virus-mediated kallikrein gene therapy reduces hypertension and attenuates its cardiovascular injuries. Gene Therapy 2004 11:1342 50.
14. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998 72:2224 32.
15. Auricchio A, Hildinger M, O'Connor E, Gao G, Wilson JM. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Human Gene Therapy 2001 12:71 6.
16. Gao GP, Qu G, Faust LZ, Engdahl RK, Xiao W, Hughes JV, et al. High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. Hum Gene Ther 1998 9:2353 62.
17. Dobrzynski EMD, Agata J, Zhu J, Chao J, Chao L. Adrenomedullin improves cardiac function and prevents renal damage in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 2002 283:E1291 E1298.
18. MacColl GS, Goldspink G, Bouloux PM. Using skeletal muscle as an artificial endocrine tissue. J Endocrinol 1999 162:1 9.
19. Danko I, Fritz, JD, Jiao S, Hogan K, Latendresse JS, Wolff JA. Pharmacological enhancement of in vivo foreign gene expression in muscle. Gene Therapy 1994 1:114 21.
20. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004 292:2343 9.
21. Monahan PE SR. AAV vectors: is clinical success on the horizon Gene Ther 2000 7 (1 24 30.
22. Liu F LK, Huang L. Systemic administration of naked DNA: gene transfer to skeletal muscle. Mol Interv 2001 1:168 72.
23. Blau HM, Springer ML. Muscle-mediated gene therapy. N Engl J Med 1995 333:1554 6.
24. Wang B, Li J, Xiao X. From the cover: adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci USA 2000 97:13714 9.
25. Bohl D, Bosch A, Cardona A, Salvetti A, Heard JM. Improvement of erythropoiesis in beta-thalassemic mice by continuous erythropoietin delivery from muscle. Blood 2000 95:2793 8.
26. Schmaier AH. The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. Am J Physiol Regul Integr Comp Physiol 2003 285:R1 R13.